Latest Diagnostic Imaging News

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

Integral Diagnostics has installed Jason Martinez as its new CEO, marking a leadership change as the company prepares to present its FY26 results. Martinez brings over 20 years of diagnostic imaging experience and aims to drive growth and innovation following the retirement of long-serving CEO Ian Kadish.

Enlitic has landed its inaugural Australian Ensight subscription contract with Lumus Imaging, marking a strategic entry into the local SaaS market and expanding its footprint in diagnostic imaging workflows.

Pro Medicus secures a $16 million, 7-year cloud imaging contract with TidalHealth, complementing recent major wins and contract renewals that underscore its growing dominance in North American healthcare IT.

4DMedical’s CT:VQ™ technology has been clinically validated in a top respiratory journal, showing a leap in patient response rates for lung volume reduction surgery from 46% to 76%, promising improved outcomes and hospital efficiencies.

Pro Medicus’ US arm Visage Imaging has landed a significant 7-year, A$90 million contract to deploy its cloud-based Visage 7 platform across Beth Israel Lahey Health, marking another major foothold in North America's healthcare imaging market.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Singular Health boosted its US presence by deploying 500 additional 3DICOM MD® licenses to Provider Network Solutions, securing FDA 510(k) clearance for its cloud platform, and launching education pilots with Miami-Dade schools and Florida International University.

4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.

Clarity Pharmaceuticals has signed a significant manufacturing supply agreement with Theragenics to produce copper-64, a key isotope for its upcoming prostate cancer diagnostic, Cu-SAR-bisPSMA. This deal strengthens Clarity’s US supply network ahead of anticipated FDA approval and commercial launch.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.